NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma is nearing the completion of the target enrollment for its Phase 1b/2a clinical trial of NVG-291, a new treatment aimed at repairing nervous system damage from spinal cord injuries. The trial has attracted interest due to its innovative approach and is partially funded by a grant from Wings for Life. Results will focus on motor function improvements, with comprehensive assessments including clinical outcomes and electrophysiological measures.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
